间变性大细胞淋巴瘤中的免疫逃逸机制。 - Suppr

Suppr

超能文献

Immune escape mechanisms in ALCL.

作者信息

Oudejans J J, ten Berge R L, Meijer C J L M

出版信息

J Clin Pathol. 2003 Jun;56(6):423-5. doi: 10.1136/jcp.56.6.423.

DOI:10.1136/jcp.56.6.423

PMID:12783967

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1769972/

Abstract

摘要

相似文献

Immune escape mechanisms in ALCL.

J Clin Pathol. 2003 Jun;56(6):423-5. doi: 10.1136/jcp.56.6.423.

Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma of null/T cell phenotype and in cell lines derived from anaplastic large cell lymphoma.

Pathobiology. 1997;65(2):83-90. doi: 10.1159/000164108.

B and CTL responses to the ALK protein in patients with ALK-positive ALCL.

Int J Cancer. 2006 Feb 1;118(3):688-95. doi: 10.1002/ijc.21410.

A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.

J Clin Pathol. 1999 Feb;52(2):129-36. doi: 10.1136/jcp.52.2.129.

Relapsing lymphoma.

N Engl J Med. 1995 Jul 20;333(3):194-5.

Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.

Tissue Antigens. 2002 Oct;60(4):273-81. doi: 10.1034/j.1399-0039.2002.600401.x.

Immunosuppressive and cytotoxic cells in invasive vs. non-invasive Bowen's disease.

Acta Derm Venereol. 2014 May;94(3):337-9. doi: 10.2340/00015555-1729.

Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Am J Surg Pathol. 2014 Feb;38(2):279-88. doi: 10.1097/PAS.0000000000000140.

Tumor infiltrating lymphocytes in early breast cancer.

Breast. 2018 Feb;37:207-214. doi: 10.1016/j.breast.2017.03.010. Epub 2017 Mar 28.

Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Immunology. 2002 Mar;105(3):263-6. doi: 10.1046/j.1365-2567.2002.01379.x.

引用本文的文献

Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.

J Biomed Biotechnol. 2010;2010. doi: 10.1155/2010/846872. Epub 2010 Aug 12.

本文引用的文献

Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.

Blood. 2002 Jun 15;99(12):4540-6. doi: 10.1182/blood.v99.12.4540.

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.

Blood. 2002 Mar 15;99(6):2100-6. doi: 10.1182/blood.v99.6.2100.

Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?

Blood. 2002 Jan 1;99(1):232-7. doi: 10.1182/blood.v99.1.232.

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

J Clin Pathol. 2001 Dec;54(12):933-9. doi: 10.1136/jcp.54.12.933.

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

Cancer Res. 2001 Sep 15;61(18):6846-50.

Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

Am J Pathol. 2001 Aug;159(2):527-35. doi: 10.1016/S0002-9440(10)61724-5.

Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.

Br J Dermatol. 2000 Aug;143(2):313-9. doi: 10.1046/j.1365-2133.2000.03656.x.

Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.

Blood. 2000 Aug 15;96(4):1605-7.

Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

J Exp Med. 1999 Oct 4;190(7):1033-8. doi: 10.1084/jem.190.7.1033.

The central effectors of cell death in the immune system.

Annu Rev Immunol. 1999;17:781-828. doi: 10.1146/annurev.immunol.17.1.781.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Immune escape mechanisms in ALCL.

作者信息

Oudejans J J, ten Berge R L, Meijer C J L M

出版信息

J Clin Pathol. 2003 Jun;56(6):423-5. doi: 10.1136/jcp.56.6.423.

DOI:10.1136/jcp.56.6.423

PMID:12783967

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1769972/

Abstract

摘要

相似文献

Immune escape mechanisms in ALCL.

J Clin Pathol. 2003 Jun;56(6):423-5. doi: 10.1136/jcp.56.6.423.

Uniform expression of cytotoxic molecules in anaplastic large cell lymphoma of null/T cell phenotype and in cell lines derived from anaplastic large cell lymphoma.

Pathobiology. 1997;65(2):83-90. doi: 10.1159/000164108.

B and CTL responses to the ALK protein in patients with ALK-positive ALCL.

Int J Cancer. 2006 Feb 1;118(3):688-95. doi: 10.1002/ijc.21410.

A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas.

J Clin Pathol. 1999 Feb;52(2):129-36. doi: 10.1136/jcp.52.2.129.

Relapsing lymphoma.

N Engl J Med. 1995 Jul 20;333(3):194-5.

Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.

Tissue Antigens. 2002 Oct;60(4):273-81. doi: 10.1034/j.1399-0039.2002.600401.x.

Immunosuppressive and cytotoxic cells in invasive vs. non-invasive Bowen's disease.

Acta Derm Venereol. 2014 May;94(3):337-9. doi: 10.2340/00015555-1729.

Peripheral T-cell lymphomas with cytotoxic phenotype in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Am J Surg Pathol. 2014 Feb;38(2):279-88. doi: 10.1097/PAS.0000000000000140.

Tumor infiltrating lymphocytes in early breast cancer.

Breast. 2018 Feb;37:207-214. doi: 10.1016/j.breast.2017.03.010. Epub 2017 Mar 28.

Fas ligand and the fate of antitumour cytotoxic T lymphocytes.

Immunology. 2002 Mar;105(3):263-6. doi: 10.1046/j.1365-2567.2002.01379.x.

引用本文的文献

Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.

J Biomed Biotechnol. 2010;2010. doi: 10.1155/2010/846872. Epub 2010 Aug 12.

本文引用的文献

Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.

Blood. 2002 Jun 15;99(12):4540-6. doi: 10.1182/blood.v99.12.4540.

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.

Blood. 2002 Mar 15;99(6):2100-6. doi: 10.1182/blood.v99.6.2100.

Blood. 2002 Jan 1;99(1):232-7. doi: 10.1182/blood.v99.1.232.

MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.

J Clin Pathol. 2001 Dec;54(12):933-9. doi: 10.1136/jcp.54.12.933.

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

Cancer Res. 2001 Sep 15;61(18):6846-50.

Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

Am J Pathol. 2001 Aug;159(2):527-35. doi: 10.1016/S0002-9440(10)61724-5.

Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL.

Br J Dermatol. 2000 Aug;143(2):313-9. doi: 10.1046/j.1365-2133.2000.03656.x.

Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.

Blood. 2000 Aug 15;96(4):1605-7.

Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein.

J Exp Med. 1999 Oct 4;190(7):1033-8. doi: 10.1084/jem.190.7.1033.

The central effectors of cell death in the immune system.

Annu Rev Immunol. 1999;17:781-828. doi: 10.1146/annurev.immunol.17.1.781.